Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses.
Success of a candidate vaccine against human immunodeficiency virus (HIV) depends on the type, site, strength, longevity and specificity of the immune responses it induces. The specificity of a vaccine is determined by the HIV-derived immunogens it employs in its formulation. Central to the other fe...
第一著者: | Hanke, T |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2001
|
類似資料
-
DNA vaccines against human immunodeficiency virus type 1.
著者:: Estcourt, M, 等
出版事項: (2004) -
Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
著者:: Nixon, D, 等
出版事項: (2000) -
Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
著者:: Hanke, T, 等
出版事項: (2007) -
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus
著者:: Fidler, S, 等
出版事項: (2022) -
Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.
著者:: Larke, N, 等
出版事項: (2005)